Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Primary Breast Cancer ER+ve × exemestane × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 182 Neoplasm Metastasis 16 Neoplasms 8 Breast Neoplasms, Male 6 Breast Diseases 5 Ovarian Neoplasms 4 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Intraductal, Noninfiltrating 3 Breast Carcinoma In Situ 3 Breast Cancer Metastatic 3 Prostatic Neoplasms 2 Neoplasms by Site 2 Carcinoma, Renal Cell 2 Bulbo-Spinal Atrophy, X-Linked 2 Advanced Breast Cancer 2 Uterine Cervical Neoplasms 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sleep Wake Disorders 1 Skin Diseases 1 Sexuality 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Recurrence 1 Primary Breast Cancer ER+ve 1 Premenopausal Breast Cancer 1 Patient Acceptance of Health Care 1

Interventions

exemestane 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02676986 2024-07-05

ARB

Queen Mary University of London

Phase 2 Completed

Primary Breast Cancer ER+ve

Data powered by HemOnc (CC BY 4.0) Colophon ⚡